Sign in

PCYC on NASDAQ

Pharmacyclics

Logo: Pharmacyclics, Public domain, via Wikimedia Commons4

American biopharmaceutical company

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.3 Its shares trade on NASDAQ under the symbol PCYC.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1991Founded1

Compare with another stock.

  • TickerPCYC on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSunnyvale1
  • Websitewww.pharmacyclics.com
  • Incorporated inDE5
  • Business addressPharmacyclics Inc, 995 E Arques Ave, Sunnyvale, Ca 94085-45215
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.3

What it owns

What Pharmacyclics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$19.5M7 Dec 31, 2014$14.6M7 Dec 31, 2013+33.4%
Property and equipment, before depreciation$44.1M7 Dec 31, 2014$33.2M7 Dec 31, 2013+32.7%
Accumulated depreciation$11.6M7 Dec 31, 2014$7.7M7 Dec 31, 2013+50.0%
Property and equipment, net$32.5M7 Dec 31, 2014$25.5M7 Dec 31, 2013+27.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$845.0M7 Dec 31, 2014$624.0M7 Dec 31, 2013+35.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$8.7M7 Dec 31, 2014$07 Dec 31, 2013
Accumulated amortization$500.0K7 Dec 31, 2014
Finite-lived intangibles, net$8.7M7 Dec 31, 2014

Inventory

ItemLatestA year beforeChange
Inventory, total$34.4M7 Dec 31, 2014$12.6M7 Dec 31, 2013+173.3%
Raw materials$07 Dec 31, 2014$8.0M7 Dec 31, 2013−100.0%
Work in process$27.6M7 Dec 31, 2014$3.5M7 Dec 31, 2013+690.8%
Finished goods$6.9M7 Dec 31, 2014$1.1M7 Dec 31, 2013+519.2%

Leadership

Who has led Pharmacyclics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard A. Miller Md.2006–2008
  2. Robert W. Duggan2009–2015

Chair

  1. Robert W. Duggan2009–2015

President

  1. Glenn C. Rice2009

Chief financial officer

  1. Leiv Lea2006–2008
  2. Manmeet Singh Soni2014–2015

Chief operating officer

  1. Glenn C. Rice2009
  2. Maky Zanganeh2012–2015
1995200020052010201520202025
Board members and other officers (55)

Acquisitions

In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. Imbruvica, the company’s flagship therapy, later became one of the most prescribed treatments for chronic lymphocytic leukemia (CLL). As part of the deal, AbbVie paid $261.25 per share in a mixture of both cash and AbbVie equity. The merger closed in mid-2015.

Duggan received over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."

From Wikipedia’s article on Pharmacyclics, shared under CC BY-SA 4.0.6

Timeline

  1. Aug 4, 2009New chief executive Robert W. Duggan becomes CEO8
  2. May 24, 2006New chief executive Richard A. Miller Md. becomes CEO9
  3. 1991Founded Founded1

SEC filer profile

How Pharmacyclics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPHARMACYCLICS INC2
  • CIK0000949699
  • Employer ID (EIN)94-31482012
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business addressPharmacyclics Inc, 995 E Arques Ave, Sunnyvale, CA 94085-45212
  • Phone408 774 03302
  • Shares outstanding77,079,177 as of Apr 24, 201567
  • Public float$4.0B as of Jun 30, 20147
  • On EDGAR sinceMay 13, 19962
  • Filings1,400 in all: 4 (641), 8-K (271), SC 13G/A (83), 10-Q (57), 3 (54), SC 13G (42), S-8 POS (20), DEF 14A (19)2
    All 53 form types

    10-K (18), S-8 (18), 425 (14), SC 13D/A (14), CORRESP (11), SC TO-T/A (11), UPLOAD (11), ARS (10), S-3 (10), CT ORDER (9), 4/A (8), 10-K/A (6), 424B5 (6), S-3/A (6), EFFECT (5), PRE 14A (5), 5 (4), 8-K/A (3), DEFA14A (3), DEFR14A (3), S-3MEF (3), 10-K405 (2), 10-Q/A (2), 15-12G (2), 3/A (2), 424B1 (2), 424B3 (2), S-1/A (2), SC 13D (2), SC 14D9 (2), SC TO-T (2), SC14D9C (2), 10-KT (1), 25-NSE (1), 424B2 (1), 424B4 (1), 5/A (1), 8-A12G (1), 8-A12G/A (1), POSASR (1), RW (1), S-1 (1), S-3ASR (1), SC 14D9/A (1), SC 14F1 (1)

  • Latest filingsAnnual report (10-K) Feb 18, 2015
    Quarterly report (10-Q) May 4, 2015
    Proxy statement (DEF 14A) Apr 8, 2014
    Latest 8-K (8-K) May 26, 2015

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67